| Literature DB >> 33178660 |
Shushan Fan1, Min Wu1, Shengjun Ma2, Shouguo Zhao3.
Abstract
COVID-19 is a rapidly spreading infectious disease that has led to a global pandemic. This study describes a novel strategy for preventing and controlling COVID-19 infection in the third-tier city of Liaocheng, China. The prevention and control measurements included city-wide orders to close workspaces, sanitize essential workspaces, quarantine individuals with a travel history to an epidemic area, and issue emergency medical responses to quarantine and treat COVID-19 patients using all necessary technologies, personnel, and resources. As a result, there were only 38 diagnosed COVID-19 cases in Liaocheng since the pandemic began in China in late 2019, including in the metropolitan area and six suburban counties, accounting for more than 6.39 millions residents living in a 8,715 km2 area. There was no COVID-19-related fatality and no healthcare professional inter-transmission as of June 25, 2020. The strategies of this third-tier Chinese city provide useful insights into approaches to prevent and control COVID-19 spread in other Chinese cities and countries.Entities:
Keywords: COVID-19; economy; first level response; prevention and control; strategy
Mesh:
Year: 2020 PMID: 33178660 PMCID: PMC7593509 DOI: 10.3389/fpubh.2020.562024
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Clinical characteristics of the COVID-19 patients in Liaocheng (n = 38).
| 43.17 ± 17.9 | |
| Male | 18 (47.37) |
| Female | 20 (52.63) |
| Any | 9 (23.68) |
| Hypertension | 3 (7.89) |
| Coronary heart disease | 3 (7.89) |
| Diabetes | 2 (5.26) |
| Pulmonary interstitial fibrosis | 1 (2.63) |
| Cirrhosis, liver cancer | 1 (2.63) |
| Contact with wild | 0 (0) |
| Wuhan sojourn | 6 (15.79) |
| Contact with a diagnosed patient or workplace | 30 (78.95) |
| Not available | 2 (5.26) |
| Asymptomatic | 8 (21.05) |
| Fever | 23 (60.53) |
| ≤ 38.0°C | 20 (86.96) |
| >38.0°C | 3 (13.04) |
| Chills | 1 (2.63) |
| Fatigue | 9 (23.68) |
| Headache | 3 (7.89) |
| Nasal congestion | 3 (7.89) |
| Sore throat | 8 (21.05) |
| Cough | 25 (65.79) |
| Hemoptysis | 1 (2.63) |
| Shortness of breath | 12 (31.58) |
| Vomiting or diarrhea | 8 (21.05) |
| Pain in a muscle or joint | 2 (5.26) |
| Mild | 6 (15.79) |
| Moderate | 30 (78.95) |
| Severe | 1 (2.63) |
| Critical | 1 (2.63) |
| Antibiotics | 27 (71.05) |
| Antifungal drugs | 1 (2.63) |
| Antiviral drugs | 37 (97.37) |
| Glucocorticoids | 8 (21.05) |
| Albumin | 12 (31.58) |
| Immunoglobulin | 7 (18.42) |
| Thymosin | 24 (63.16) |
| Oxygen therapy | 15 (39.47) |
| Common | 13 (34.21) |
| HFNC | 2 (5.26) |
| PE | 1 (2.63) |
| TCM | 37 (97.37) |
HFNC, high-flow nasal cannula; PE, plasma exchange; TCM, traditional Chinese medicine.